Journal of Clinical Oncology, Vol 20, Issue 15
(August), 2002: 3276-3281
© 2002 American Society for Clinical Oncology
Complication Rates Among Cancer Patients With Peripherally Inserted Central Catheters
By Louise J. Walshe,
Sharp F. Malak,
Janet Eagan,
Kent A. Sepkowitz
From the Memorial Sloan-Kettering Cancer Center, New York, NY.
Address reprint requests to Kent A. Sepkowitz, MD, Clinical Infectious Disease Section, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 288, New York, NY 10021; email: sepkowik{at}mskcc.org
PURPOSE: Peripherally inserted central catheters (PICCs) are frequently used to deliver outpatient courses of intravenous therapy. However, the rates and risks of complication for this device have not been well-studied. Our objective was to determine the incidence and risk factors of PICC-related complications with a 1-year prospective observational study.
PATIENTS AND METHODS: All PICCs inserted in adult and pediatric patients at Memorial Sloan-Kettering Cancer Center (MSKCC) were followed prospectively. The device insertion team, inpatient nurses, and various home-care companies and outside institutions collected longitudinal data.
RESULTS: Three hundred fifty-one PICCs were inserted during the study period and followed for a total of 10,562 catheter-days (median placement, 15 days; range, 1 to 487 days). Two hundred five PICCs (58%) were managed by home-care companies and outside institutions, and 146 PICCs (42%) were managed exclusively at MSKCC. For these 205 PICCs, 131 nurses from 74 home-care companies and institutions were contacted for follow-up clinical information. In all, 115 (32.8%) of 351 PICCs were removed as a result of a complication, for a rate of 10.9 per 1,000 catheter-days. Patients with hematologic malignancy or bone marrow transplant were more likely to develop a complication, whereas those with metastatic disease were less likely.
CONCLUSION: Complications occur frequently among cancer patients with PICCs, and long-term follow-up is onerous. Despite a high complication rate, the ease of insertion and removal argues for continued PICC use in the cancer population.
This article has been cited by other articles:
|
|
|
|
 
J. D. Paauw, H. Borders, N. Ingalls, S. Boomstra, S. Lambke, B. Fedeson, A. Goldsmith, and A. T. Davis
The Incidence of PICC Line-Associated Thrombosis With and Without the Use of Prophylactic Anticoagulants
JPEN J Parenter Enteral Nutr,
July 1, 2008;
32(4):
443 - 447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
381S - 453S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dubois MD MSc, F. Rypens MD, L. Garel MD, M. David MD, J. Lacroix MD, and F. Gauvin MD MSc
Incidence of deep vein thrombosis related to peripherally inserted central catheters in children and adolescents
Can. Med. Assoc. J.,
November 6, 2007;
177(10):
1185 - 1190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Y.Y. Lee, M. N. Levine, G. Butler, C. Webb, L. Costantini, C. Gu, and J. A. Julian
Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer
J. Clin. Oncol.,
March 20, 2006;
24(9):
1404 - 1408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Thromboembolism after pneumonectomy for malignancy: An independent marker of poor outcome.
J. Thorac. Cardiovasc. Surg.,
March 1, 2006;
131(3):
711 - 718.
|
|
|
|
|
|
|
M. Levine and A.K. Kakkar
Catheter-Associated Thrombosis: Thromboprophylaxis or Not?
J. Clin. Oncol.,
June 20, 2005;
23(18):
4006 - 4008.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray
Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
338S - 400S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Knox, D. Hedley, A. Oza, L. L. Siu, G. R. Pond, and M. J. Moore
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience
Ann. Onc.,
May 1, 2004;
15(5):
770 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Y.Y. Lee and M. N. Levine
Venous Thromboembolism and Cancer: Risks and Outcomes
Circulation,
June 17, 2003;
107(90231):
I-17 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
